A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
To establish the efficacy of 40 mg/day doses of istradefylline for the change in Unified
Parkinson's Disease Rating Scale (UPDRS) part-III (Motor examination) score in patients with
Parkinson's disease (PD).
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.